Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.
IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
Overview of treatment options in multiple sclerosis.
Immunopathology of multiple sclerosis.
Does glatiramer acetate provoke hepatitis in multiple sclerosis?
miRNA in multiple sclerosis: search for novel biomarkers.
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
Fingolimod for multiple sclerosis: a review for the specialist nurse.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients.
The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
Effects of sleep and wake on oligodendrocytes and their precursors.
Synthesis of 5α-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: Discovery of a novel neuroinflammation inhibitor.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Testing the feasibility and acceptability of using the Nintendo Wii in the home to increase activity levels, vitality and well-being in people with multiple sclerosis (Mii-vitaliSe): protocol for a pilot randomised controlled study.
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.
The best basic science paper in multiple sclerosis in 2014: Important role for the choroid plexus in the central nervous system entry of leukocytes.
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Activation of Invariant NKT Cells in Early Phase of Experimental Autoimmune Encephalomyelitis Results in Differentiation of Ly6Chi Inflammatory Monocyte to M2 Macrophages and Improved Outcome.
1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis.
MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis.
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Pages
« first
‹ previous
…
183
184
185
186
187
188
189
190
191
…
next ›
last »